New therapeutic strategies in T2D such as glucagon-like peptide-1 (GLP1) receptor agonists were reported to counteract some alterations of circulating lipidome in T2D, including sphingolipids [60, 61], and to reduce the risk of atherosclerotic cardiovascular risk in T2D [62]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.